Fady Ibraham Malik's Stock Transactions in Cytokinetics Inc

On August 5, 2025, Fady Ibraham Malik, the Executive Vice President of Research & Development at Cytokinetics Inc, reported several stock transactions. Malik exercised a non-qualified stock option to buy 2,000 shares of common stock at $10.60 per share, resulting in a total of 14,261 shares owned following the transaction. On the same day, Malik also sold 2,000 shares of common stock at $36.34 per share, reducing his total ownership to 140,610 shares. Additionally, Malik disposed of 2,000 shares through a derivative transaction, leaving him with 11,105 shares following the transaction. These transactions were reported in a Form 4 filing with the SEC.